Development of a Patient-reported Outcome Measure for Chiari Malformation and Syringomyelia
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 21, 2023
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating a tool that helps doctors understand how Chiari malformation and syringomyelia affect patients' daily lives. Chiari malformation happens when part of the brain, called the cerebellar tonsils, pushes down into the spinal area, which can block the flow of a fluid called cerebrospinal fluid. This can lead to a condition known as syringomyelia, where a fluid-filled cavity forms in the spinal cord. The researchers want to develop a way for patients to report their symptoms, which will help doctors provide better treatment and follow-up care.
To participate in this trial, you must be at least 18 years old and able to understand French. You should also have a confirmed diagnosis of either Chiari malformation or syringomyelia based on an MRI scan. If you decide to join, you will be asked to share your experiences and symptoms related to these conditions. This research is important because it aims to improve how these conditions are evaluated and treated, ultimately leading to better patient care. Please note that the trial is not yet recruiting participants, so more information will be available when it starts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Criteria common to all subjects included in the study
- • Age \> 18 years
- • Subject understanding French Patients included in Phase I
- • Subject with signed informed consent Patients included in phase II
- • Patient not opposed to study participation
- Patients Chiari only group:
- • Isolated descent of cerebellar tonsils \> 5 mm below McRae's line (no associated syringomyelia)
- Patients syringomyelia only group:
- • Presence of an intramedullary fluid cavity secondary to circulatory disturbance of cerebrospinal fluid of non foraminal origin (no Chiari)
- Patients Chiari with Syringomyelia group:
- • Presence of Chiari malformation (tonsils \> 5 mm below McRae's line) AND foraminal syringomyelia.
- Exclusion Criteria:
- • Insufficient command of French
- • Minor or protected adult (guardianship, curatorship, safeguard of justice)
- • Diagnosis of Chiari and/or syringomyelia not proven by an MRI scan
- • Pregnant or breast-feeding
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Le Kremlin Bicêtre, France
Patients applied
Trial Officials
Steven KNAFO
Principal Investigator
Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported